Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Key Points

• In this study, the risk of a return to menses and/or premenopausal estradiol/follicle-stimulating hormone levels by 30 months after a switch from adjuvant tamoxifen to aromatase inhibitor therapy in women with postmenopausal estradiol levels at the time of the switch was 15.2% (38 of 250 patients) for women who had chemotherapy-induced amenorrhea and were aged younger than 50 years at the time of breast cancer diagnosis.
• The risk was 1.2% (1 in 79 women) for women who were aged 50 to 54 years but still were premenopausal at the time of breast cancer diagnosis.

http://ift.tt/2AWtCFB